Literature DB >> 15979033

A G-to-A transition at the fifth position of intron-32 of the dystrophin gene inactivates a splice-donor site both in vivo and in vitro.

Hoai Thu Thi Tran1, Yasuhiro Takeshima, Agus Surono, Mariko Yagi, Hiroko Wada, Masafumi Matsuo.   

Abstract

The splicing pattern of pre-mRNA is unpredictable in genes harboring a single-nucleotide change within the consensus sequence of a splice-donor site. In the dystrophin gene, a transition from G to A at the fifth position of intron-32 (4518+5G > A) has been reported as a polymorphism within the consensus sequence or a mutation identified in Duchenne muscular dystrophy (DMD). Here, we report both in vivo and in vitro evidence that shows inactivation of the splice-donor site caused by this mutation. In one Japanese DMD case, two novel dystrophin mRNAs were identified in the patient's lymphocytes, one with a 98 bp deletion of the 3' end of exon-32 (dys32-98) and the other with a 28 bp intron retained between exons 32 and 33 (dys32 + 28). Genomic sequencing disclosed a single-nucleotide change from G to A at the fifth position of intron-32 (4518+5G > A). To demonstrate in vitro the inactivation of this splice-donor site by this nucleotide change, mini-dystrophin genes comprising three exons harboring either normal or mutant intron-32 sequences were expressed in HeLa cells, and the splicing products were analyzed by reverse-transcription PCR amplification. A normal transcript consisting of three exons was obtained from the normal construct. From the mutant, we obtained one product containing a 98 bp deletion at the 3' end of exon-32, indicating complete inactivation of the native splice-donor site. Thus, both in vivo and in vitro experiments demonstrate that 4518+5G > A causes a splicing error leading to transcript termination; it did not behave like a silent polymorphism. Our results indicate that the in vitro splicing system is a powerful tool for determining the underlying mechanism of a disease-causing mutation in a splicing consensus sequence.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15979033     DOI: 10.1016/j.ymgme.2005.03.006

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  23 in total

1.  Splicing analysis disclosed a determinant single nucleotide for exon skipping caused by a novel intraexonic four-nucleotide deletion in the dystrophin gene.

Authors:  Van Khanh Tran; Yasuhiro Takeshima; Zhujun Zhang; Mariko Yagi; Atsushi Nishiyama; Yasuaki Habara; Masafumi Matsuo
Journal:  J Med Genet       Date:  2006-05-31       Impact factor: 6.318

2.  Identification of seven novel cryptic exons embedded in the dystrophin gene and characterization of 14 cryptic dystrophin exons.

Authors:  Zhujun Zhang; Yasuaki Habara; Atsushi Nishiyama; Yoshinobu Oyazato; Mariko Yagi; Yasuhiro Takeshima; Masafumi Matsuo
Journal:  J Hum Genet       Date:  2007-06-20       Impact factor: 3.172

3.  Exonic mutations in the SLC12A3 gene cause exon skipping and premature termination in Gitelman syndrome.

Authors:  Yoichi Takeuchi; Eikan Mishima; Hisato Shima; Yasutoshi Akiyama; Chitose Suzuki; Takehiro Suzuki; Takayasu Kobayashi; Yoichi Suzuki; Tomohiro Nakayama; Yasuhiro Takeshima; Norma Vazquez; Sadayoshi Ito; Gerardo Gamba; Takaaki Abe
Journal:  J Am Soc Nephrol       Date:  2014-07-24       Impact factor: 10.121

4.  A nonsense mutation-created intraexonic splice site is active in the lymphocytes, but not in the skeletal muscle of a DMD patient.

Authors:  Van Khanh Tran; Yasuhiro Takeshima; Zhujun Zhang; Yasuaki Habara; Kazuhiro Haginoya; Atsushi Nishiyama; Mariko Yagi; Masafumi Matsuo
Journal:  Hum Genet       Date:  2006-09-26       Impact factor: 4.132

5.  Branch point identification and sequence requirements for intron splicing in Plasmodium falciparum.

Authors:  Xiaohong Zhang; Caitlin A Tolzmann; Martin Melcher; Brian J Haas; Malcolm J Gardner; Joseph D Smith; Jean E Feagin
Journal:  Eukaryot Cell       Date:  2011-09-16

6.  Cryptic splice activation but not exon skipping is observed in minigene assays of dystrophin c.9361+1G>A mutation identified by NGS.

Authors:  Emma Tabe Eko Niba; Atsushi Nishida; Van Khanh Tran; Dung Chi Vu; Masaaki Matsumoto; Hiroyuki Awano; Tomoko Lee; Yasuhiro Takeshima; Hisahide Nishio; Masafumi Matsuo
Journal:  J Hum Genet       Date:  2017-01-19       Impact factor: 3.172

7.  Functional splicing analysis in an infantile case of atypical hemolytic uremic syndrome caused by digenic mutations in C3 and MCP genes.

Authors:  Tomohiko Yamamura; Kandai Nozu; Hiroaki Ueda; Rika Fujimaru; Ryutaro Hisatomi; Yoko Yoshida; Hideki Kato; Masaomi Nangaku; Toshiyuki Miyata; Toshihiro Sawai; Shogo Minamikawa; Hiroshi Kaito; Masafumi Matsuo; Kazumoto Iijima
Journal:  J Hum Genet       Date:  2018-03-19       Impact factor: 3.172

8.  In vivo and in vitro splicing assay of SLC12A1 in an antenatal salt-losing tubulopathy patient with an intronic mutation.

Authors:  Kandai Nozu; Kazumoto Iijima; Kazuo Kawai; Yoshimi Nozu; Atsushi Nishida; Yasuhiro Takeshima; Xue Jun Fu; Yuya Hashimura; Hiroshi Kaito; Koichi Nakanishi; Norishige Yoshikawa; Masafumi Matsuo
Journal:  Hum Genet       Date:  2009-06-10       Impact factor: 4.132

9.  Synonymous point mutation of gtfB gene caused by therapeutic X-rays exposure reduced the biofilm formation and cariogenic abilities of Streptococcus mutans.

Authors:  Zheng Wang; Yujie Zhou; Qi Han; Xingchen Ye; Yanyan Chen; Yan Sun; Yaqi Liu; Jing Zou; Guohai Qi; Xuedong Zhou; Lei Cheng; Biao Ren
Journal:  Cell Biosci       Date:  2021-05-17       Impact factor: 7.133

10.  Ethnically diverse causes of Walker-Warburg syndrome (WWS): FCMD mutations are a more common cause of WWS outside of the Middle East.

Authors:  M Chiara Manzini; Danielle Gleason; Bernard S Chang; R Sean Hill; Brenda J Barry; Jennifer N Partlow; Annapurna Poduri; Sophie Currier; Patricia Galvin-Parton; Lawrence R Shapiro; Karen Schmidt; Jessica G Davis; Lina Basel-Vanagaite; Mohamed Z Seidahmed; Mustafa A M Salih; William B Dobyns; Christopher A Walsh
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.